<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02489461</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-VM1500-04</org_study_id>
    <nct_id>NCT02489461</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Optimal Dose Selection VM-1500 in Comparison to Efavirenz When Added to Standard-of-care Antiretroviral Therapy</brief_title>
  <official_title>International, Multicenter, Randomized, Partially Blind Clinical Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viriom</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viriom</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the following safety and efficacy parameters for VM-1500:

        -  Decrease in viral load to non-quantifiable level (&lt;50 copies/ml) at Week 12 (Stage I)

        -  Decrease in viral load to non-quantifiable level (&lt;50 copies/ml) at Week 24 (Stage II)

        -  Decrease in viral load during 48 weeks of treatment

        -  Percentage of subjects with at least 10-fold (1 log10) decrease in viral load at Week 4

        -  Percentage of subjects with decrease in viral load to &lt;400 copies/ml at Week 12

        -  Percentage of subjects who continued to receive the investigational treatment up to Week
           48

        -  СD4+ and СD8+ cell count change during 48 weeks of the study

        -  Percentage of subject who developed HIV-1 resistance to the investigational treatment by
           week 48

        -  Frequency of adverse events (AE) of different severity according to subjective
           complaints, physical assessment, vital signs, laboratory tests, ECG

        -  Frequency of adverse events of special interest, including of central nervous system
           (CNS) effects

        -  VM-1500 pharmacokinetic profile in selected subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose selection for VM-1500 in combination with two nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) based on analysis of AEs, laboratory values, subjects' diaries.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy evaluation of VM-1500 (optimal dose selected at Stage I) in combination with two NRTIs, as compared to Efavirenz in combination with two NRTIs based on analysis of viral load.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety evaluation of VM-1500 (optimal dose selected at Stage I) in combination with two NRTIs, as compared to Efavirenz in combination with two NRTIs based on analysis of AEs, laboratory values and subjects' diaries.</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV-infection</condition>
  <arm_group>
    <arm_group_label>VM-1500 20 mg (Stage I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500 40 mg (Stage I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz 600 mg (Stage I and Stage II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efavirenz 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-1500 (optima dose) (Stage II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM-1500 (optimal dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VM-1500</intervention_name>
    <description>VM-1500 up to 48 weeks</description>
    <arm_group_label>VM-1500 20 mg (Stage I)</arm_group_label>
    <arm_group_label>VM-1500 40 mg (Stage I)</arm_group_label>
    <arm_group_label>VM-1500 (optima dose) (Stage II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Efavirenz up to 48 weeks</description>
    <arm_group_label>Efavirenz 600 mg (Stage I and Stage II)</arm_group_label>
    <other_name>Stocrin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiretroviral therapy (ART)</intervention_name>
    <description>ART up to 48 weeks</description>
    <arm_group_label>VM-1500 20 mg (Stage I)</arm_group_label>
    <arm_group_label>VM-1500 40 mg (Stage I)</arm_group_label>
    <arm_group_label>Efavirenz 600 mg (Stage I and Stage II)</arm_group_label>
    <arm_group_label>VM-1500 (optima dose) (Stage II)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Patient Information and Informed Consent Form.

          2. Males and females, age ≥ 18 years.

          3. HIV-1 infection, confirmed serologically in IFA or immunoblot analysis (or documented
             HIV-1 infection).

          4. Clinically stable HIV infection (clinical stages 1 or 2 according to the WHO
             classification).

          5. Indications (in the Investigator's opinion) for ART, according to the WHO Summary
             Guideline for use of antiretroviral drugs in HIV prevention and treatment (2013).

          6. HIV-1 RNA plasma level ≥ 5 000 copies/ml at screening.

          7. СD4+ Т-cells number &gt; 200 cells/mm3 at screening.

          8. Laboratory parameters as follows:

        White blood cells ≥ 2900/mm3 (2,9 x 109 cells/l) Absolute neutrophils ≥ 1500/mm3 (1,5 x 109
        cells/l) Platelets ≥ 100000/mm3 (100 x 109 cells/l) Hemoglobin ≥ 9.0 g/dl Total bilirubin ≤
        1.5 x ULN AST and ALT≤ 2.5 x ULN Renal function GFR &gt; 60 ml/min

        Exclusion Criteria:

          1. Primary HIV-1 resistance to ART. Viral resistance mutations are defined as any basic
             mutations of resistance to NNRTIs, according to the updated list of VIH-1 resistance
             mutations (International AIDS society, 2013), associated with drug resistance in any
             genotype.

          2. History of antiretroviral therapy (ART), including for the prevention of vertical
             transmission of HIV.

          3. Acute hepatitis or hepatic cirrhosis of any etiology; anti-HCV antibodies or HBsAg at
             screening.

          4. Signs of acute infection or positive test result for syphilis, hepatitis A, Toxoplasma
             gondii, cytomegalovirus, gonorrhea, Chlamydia trachomatis during 30 days before
             screening.

          5. Opportunistic infections of the Category C (Centers of Disease Control (CDC), 2008),
             excluding Kaposi's sarcoma not requiring systemic therapy.

          6. History of tuberculosis of any localization, or tuberculosis at screening, according
             to x-ray examination.

          7. History of malignant tumors (except basal cell carcinoma, squamous cell carcinoma, or
             cervical carcinoma in situ, eliminated and cured ≥ 5 years ago).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaluga regional center for AIDS prevention</name>
      <address>
        <city>Kaluga</city>
        <state>Kaluga region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lipetsk regional center for AIDS prevention</name>
      <address>
        <city>Lipetsk</city>
        <state>Lipetsk region</state>
        <zip>398043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Regional center for AIDS prevention</name>
      <address>
        <city>Perm</city>
        <state>Perm region</state>
        <zip>614088</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Dermatovenerologic Dispensary</name>
      <address>
        <city>Ryazan</city>
        <state>Ryazan region</state>
        <zip>390046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City center for AIDS prevention</name>
      <address>
        <city>Tolyatti</city>
        <state>Samara region</state>
        <zip>445846</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican hospital for AIDS prevention</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan republic</state>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Udmurtia Republican hospital for AIDS prevention</name>
      <address>
        <city>Izhevsk</city>
        <state>Udmurtia republic</state>
        <zip>426067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd regional center for AIDS prevention</name>
      <address>
        <city>Volgograd</city>
        <state>Volgograd region</state>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Scientific Research Institute of Epidemiology</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Infectional Clinical Hospital #2</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow Prevention AIDS Center</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Petersburg city center for AIDS prevention</name>
      <address>
        <city>St.Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical infectious diseases hospital n.a. S.P. Botkin&quot;</name>
      <address>
        <city>St.Petersburg</city>
        <zip>191167</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2015</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

